CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
botulinum toxin Type A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01391312
NCT01391312Phase 4Completed

A Pilot Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Glabellar Lines - Establishing Patient Satisfaction

Allergan·interventional·Posted Jul 12, 2011·Updated Sep 25, 2012

In Brief

A Phase 4 clinical trial evaluating botulinum toxin Type A and normal saline (placebo) for Glabellar Frown Lines. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This was a pilot study to observe patient satisfaction with BOTOX® Cosmetic treatment in glabellar rhytides (frown lines) using a new treatment satisfaction measure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 12, 2011
Enrollment StartJun 1, 2011
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.0 years ago

Interventions

botulinum toxin Type Abiological

botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.

normal saline (placebo)drug

Normal saline (placebo) injected into the glabellar region on Day 0.